What Алерон treats: Main Uses and Benefits

Алерон is applied across domains where additional symptomatic support is needed for allergic conditions. It is commonly used to help manage symptoms related to allergic rhinoconjunctivitis (both seasonal and perennial) and chronic urticaria (long-term hives). This medication is relevant for easing discomfort when symptoms cluster into patterns requiring supportive management.

Symptom Relief and Stability

This medication is often used during phases when symptoms become more noticeable, helping to address the physical discomfort of allergic reactions. The therapeutic benefit supports the patient during difficult episodes by easing the distressing manifestations of upper respiratory symptoms, such as persistent sneezing, rhinorrhea (runny nose), and nasal pruritus, as well as associated ocular symptoms (itchy, watery eyes). Furthermore, it is applied in clinical settings that involve episodic or fluctuating manifestations on the skin, notably pruritus (severe itching) and the presence of wheals.

“This medication is applied in scenarios where additional management of discomfort is required, helping patients cope more steadily with difficult episodes.”

By assisting with maintaining functional stability and supporting general well-being during symptomatic phases, Алерон helps manage recurrent or episodic manifestations like perennial allergic rhinitis.

Primary Therapeutic Focus
Symptom Easing	Pruritus (Itching) in the skin, nose, and eyes
Conditions	Seasonal/Perennial Allergic Rhinitis, Chronic Urticaria
Benefit	Supports stability during symptomatic periods

Regulatory References

1. NIH MedlinePlus overview

Official Eligibility Profile

The eligibility for using Алерон (Levocetirizine) is strictly governed by regulatory criteria focusing on age, organ function, and pre-existing conditions.

Contraindicated Populations (Must NOT Use)	Condition-Based Restrictions
Known hypersensitivity to levocetirizine, cetirizine, or any piperazine derivative.	Moderate to severe renal impairment (dose adjustment required).
End-Stage Renal Disease ( CLcr < 10 mL/min) or hemodialysis.	Predisposing factors for urinary retention (use with caution).
Pediatric patients aged 6 months to 11 years with any degree of renal impairment.	Patients with solely hepatic impairment typically require no dose change.

Age-Related Eligibility

The medicine is generally approved for adults and adolescents ge 12 years. Pediatric use is established for children ge 6 months (with appropriate formulations), but the 5 mg tablet formulation is not recommended for children under 6 years due to the inability to accurately adjust the dose. Safety and effectiveness have not been established for infants under 6 months of age.

Pregnancy and Lactation Status

Use during pregnancy should be considered only if clearly needed, based on available data. Use is generally not recommended for breastfeeding women due to the likelihood of levocetirizine being excreted in human milk.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Алерон (Levocetirizine) primarily through pharmacodynamic risk and constraints related to the drug’s renal clearance.

---

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions	Central Nervous System (CNS) Depressants (including alcohol/ethanol).
Specific interacting medicines (if explicitly listed)	Ritonavir, Theophylline (data derived from the racemate, Cetirizine).
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic exposure modification (reduced clearance resulting in increased plasma levels of antihistamine); Pharmacodynamic additive effects (CNS impairment).
Timing-based interaction rules (if applicable)	Food may be co-administered; the interaction is limited to a decreased rate of absorption without affecting the extent of exposure ( AUC).
Population-specific interaction notes (if applicable)	End-Stage Renal Disease ( CrCl < 10 mL/min) and Pediatric Renal Impairment are contraindicated due to renal clearance restrictions.
Interaction-related restrictions	Concurrent use with alcohol or other CNS depressants is avoided (due to additive impairment risk).

---

Official Interaction Statements

• Co-administration with alcohol or other CNS depressants is officially documented to carry the risk of additional reduction in alertness and impairment of CNS performance.
• The use is contraindicated in patients with end-stage renal disease due to the drug's heavy reliance on renal excretion.
• Ritonavir co-administration is associated with an approximate 40% increase in the extent of antihistamine exposure ( AUC), which is a documented pharmacokinetic interaction.
• Theophylline (400 mg once daily) co-administration is officially noted to cause a 16% decrease in antihistamine clearance.
• Levocetirizine is officially stated not to inhibit or induce major CYP isoenzymes at therapeutic concentrations, suggesting a low potential for metabolic drug-drug interactions.

---

Connection to the overall interaction profile: Government regulatory documents define the product’s interaction structure primarily through the risk of additive CNS impairment and the constraints imposed by its renal clearance pathway. The official profile highlights specific exposure-modifying effects from Ritonavir and Theophylline, which are detailed as pharmacokinetic outcomes, while confirming that the drug has low potential for involvement in CYP-mediated interactions.

How Алерон Works

The action of Алерон (Levocetirizine) is based on a selective pharmacodynamic process that interrupts the body’s acute chemical signaling cascade.

---

Antagonism of the Histamine H1 Receptor

The drug’s primary mechanism is the high-affinity, selective inverse agonism at the Histamine H1 receptor ( H1 R), found on cells of the vasculature, smooth muscle, and sensory nerves. This action rapidly blocks the binding of the inflammatory messenger histamine, interrupting the signaling cascade that would otherwise increase vascular permeability and activate nerve endings, which results in rapid cessation of H1 R-mediated signal transduction.

Modulation of Vascular Permeability and Sensory Nerve Signaling

By stabilizing the H1 R in its inactive state, the drug limits the key cellular event—the widening of gaps between vascular endothelial cells—that causes fluid to leak into tissues. Simultaneously, the blockade of H1 R on peripheral sensory neurons directly suppresses the transmission of signals on these neurons. This dual effect on fluid balance and neural excitation modulates the physiological response driven by histamine.

Secondary Anti-inflammatory Modulation

Beyond simple receptor blockade, Levocetirizine contributes to the regulation of the inflammatory process through an independent action that restricts the movement of key immune cells. By limiting the chemotaxis and adhesion of eosinophils, the drug engages mechanisms that restrict the movement of these cells and the release of their secondary mediators.

Official Administration Guidelines for Levocetirizine

The following instructions describe the use of levocetirizine, the active ingredient in Алерон.

Administration Scope

The approved route of administration is oral (by mouth). Levocetirizine is a once-daily medication that should be taken in the evening for optimal scheduling. The dose may be taken with or without food.

Standard Labeled Dosing and Preparation

Age Group	Standard Recommended Daily Dose	Form Consideration
Adults and Children 12 Years and Older	5 mg once daily. (2.5 mg may be sufficient for some patients.)	Available as a 5 mg scored tablet or oral solution.
Children 6 to 11 Years	2.5 mg once daily.	Tablet may be broken (scored) to achieve the 2.5 mg dose.
Children 6 Months to 5 Years	1.25 mg (2.5 mL oral solution) once daily.	Oral solution must be measured accurately with a suitable device.

Dose Limits: The maximum recommended dose of 5 mg for adults and 2.5 mg for children aged 6 to 11 years should not be exceeded.

Missed Dose: If a dose is missed, it should be skipped, and the patient should return to the regular evening dosing schedule. A double dose should not be taken to make up for the missed one.

Population-Specific Dose Adjustments

Renal Impairment: For adults and children 12 years and older with reduced kidney function, the dose and frequency must be adjusted based on creatinine clearance (CLCR). For example, patients with mild impairment (CLCR = 50-80 mL/min) should take 2.5 mg once daily, while those with moderate impairment (CLCR = 30-50 mL/min) are recommended 2.5 mg once every other day. Use of the drug is contraindicated in patients with end-stage renal disease (CLCR < 10 mL/min) and in children 6 months to 11 years with any degree of renal impairment.

Research Evidence / Overview of Studies for Алерон (Levocetirizine)

The body of research for Алерон (Levocetirizine) includes Randomized Controlled Trials (RCTs) and scientific syntheses published in peer-reviewed literature. These studies explore how symptoms change over time and are relevant in evidence describing how symptoms are measured for specific allergic conditions.

---

Evidence for Use in Conditions Marked by Allergic Rhinitis

Research on Levocetirizine for allergic rhinitis (both seasonal and perennial) centers on short-term and longer-term RCTs, which research examined in adult and pediatric populations. These trials were primarily conducted during periods of increased symptom activity and utilized a non-active comparator group.

The studies focused on outcomes related to physical discomfort and outcomes reflecting daily functioning or activity level. In these trials, findings describe patterns observed in the studies where participants experienced measured changes in symptom severity compared to those in the non-active group.

---

Evidence for Use in Conditions Associated with Chronic Urticaria

Aléron was studied for chronic urticaria, which is a condition characterized by fluctuating or episodic manifestations on the skin. The evidence mainly comes from 4- to 6-week placebo-controlled RCTs that included adults and children.

These studies focused on outcomes capturing phases of heightened symptom activity, primarily measuring the intensity of pruritus (itching) and monitoring the size and number of visible wheals. The trials reported that, in the studied populations, research explored core symptom scores for itching and hives and observed data show patterns related to those taking Levocetirizine.

---

Evidence in Specific Populations and Uncertainty

Aléron was evaluated in specific age groups, particularly the pediatric population. However, data for certain groups remain insufficient or varied; for instance, evidence for the tablet formulation in children under 6 years is less comprehensive than for liquid forms. While studies up to six months exist, limited information for long-term outcomes beyond that period is available. The results apply only to the populations studied, meaning the patterns observed may not reflect outcomes in individuals with unstudied comorbidities.

Key Studies & References

1. Levocetirizine Dihydrochloride (Oral Route) - MedlinePlus Overview
2. Public Assessment Report - Levocetirizine Dihydrochloride (Assessment of Pediatric Evidence)

Common questions about Алерон (FAQ)

Q: Is Алерон the same kind of medicine as other allergy drugs?

A: According to official product information, Алерон is classified as a second-generation H1-antihistamine. This modern class of medicine is intended for the relief of symptoms associated with allergic conditions. This classification indicates that its primary action is focused on the body's peripheral allergic responses.

Q: Why do people sometimes use Алерон for conditions that aren't typical allergies?

A: Official regulatory documents define the approved uses for this medicine. It is indicated for the relief of symptoms associated with typical allergic rhinitis (seasonal and perennial). It is also officially indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (hives).

Q: How quickly should someone expect Алерон to start working?

A: Studies and official information indicate that the onset of symptom improvement typically begins within the first two hours after the medicine is taken. The medicine is labeled for once-daily use, which suggests the intended duration of effect.

Q: How long does the effect of one dose of Алерон typically last?

A: The official administration guidelines describe the medicine as a once-daily treatment. This suggests that the intended duration of action for a single dose is approximately 24 hours.

Q: Can Алерон cause drowsiness, and if so, how common is it?

A: Drowsiness, also known as somnolence, is a commonly reported side effect. Official data from controlled clinical trials indicates that this effect was observed in approximately 5.2% of adult patients at the recommended dose.

Q: Is it known if Алерон can affect mental clarity or concentration?

A: Official warnings advise that the drug may cause somnolence and impairment of performance. Official warnings state that caution should be exercised regarding activities requiring mental alertness, such as driving or operating heavy machinery.

Q: Do experts suggest any specific time of day is best for taking Алерон?

A: Official administration guidelines simply state that the drug should be taken once daily in the evening. The official dosing schedule aligns with the drug’s pharmacological profile.

Q: What happens if I forget a dose of Алерон?

A: Official guidelines indicate that if a dose is missed, it is advised that it be skipped, and the person should return to their regular evening schedule. Documents state that taking a double dose to make up for the missed one should be avoided.

Q: Does Алерон interact with common pain relievers like ibuprofen?

A: Official documents suggest a low potential for metabolic drug-drug interactions. Levocetirizine is unlikely to cause pharmacokinetic interactions by affecting major liver drug-metabolizing enzymes, which are often involved in how the body processes common pain relievers.

Q: Can Алерон be used alongside cold and flu remedies?

A: Regulatory information warns that the co-administration of this medicine with other Central Nervous System (CNS) depressants may result in an additional reduction in alertness and impairment of performance. This warning is based on the risk of additive effects.

Q: What are the most commonly reported side effects of Алерон in studies?

A: The most common side effects reported in clinical studies include somnolence (drowsiness), fatigue, dry mouth, and headache. These effects are classified as Common in official safety documents.

Q: What are the general population limitations for using Алерон?

A: The drug is officially contraindicated in individuals with known hypersensitivity to levocetirizine or its components. It is also contraindicated in patients with end-stage renal disease, which is defined as a Creatinine Clearance below 10 mL/min.

Q: Can Алерон be used for treating hives or skin rashes?

A: Yes, the official indications for the drug include the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria. This use is detailed in official regulatory documents.

Q: Is it okay to take Алерон if I also take a multivitamin?

A: Official data indicates the drug is unlikely to interact with other medicines by affecting major liver drug-metabolizing enzymes. This suggests a low potential for interaction with standard, non-medicinal components found in multivitamins.

Q: Are there reports of long-term use concerns with Алерон?

A: Official safety warnings have been issued regarding the risk of severe itching, known as pruritus, upon discontinuation. This has been reported rarely in patients who stop taking the drug after long-term, daily use, typically spanning months to years.

Q: What is known about the use of Алерон in pregnant or breastfeeding populations?

A: Official prescribing information indicates that use during pregnancy should be considered only if clearly needed. For women who are breastfeeding, the medicine is generally not recommended due to the likelihood of it being excreted in human milk.

Q: Do studies suggest any specific groups of people respond better to Алерон?

A: Clinical trials for the medicine included diverse study populations, such as adults and children, with specific conditions. However, official regulatory documents do not draw conclusions about specific groups responding 'better' than others.

How to Store and Dispose of Алерон (Levocetirizine)

Official regulatory information details specific requirements for the storage, handling, and disposal of levocetirizine products to maintain stability and ensure safety.

Storage Requirements

Storage conditions can vary by formulation. Some levocetirizine products are required to be stored below 30 C in a dry place and be protected from light.

Specific film-coated tablet formulations may not require special storage conditions, provided they remain in their original packaging. All forms must be stored out of the sight and reach of children.

Disposal Instructions

Unused or expired medicinal product and waste material must be disposed of in accordance with local requirements. Official labeling mandates that disposal procedures should comply with environmental guidelines for pharmaceutical waste, which generally prohibits flushing the medicine down a toilet or discarding it in household trash.